Skip to main
  1. Stocks
  2. Myomo
  3. Forecast
MYO

Myomo (MYO) Stock Forecast & Price Target

Myomo (MYO) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Myomo is attractive because its Q2 revenue of $11.7 million rose 21% year over year and exceeded both estimates and guidance, while EPS of $(0.09) also beat expectations, signaling better operating leverage than the market likely anticipated. The company’s unit sales, reimbursement pipeline of 1,491, and insurance-authorized backlog of 218 show durable demand, and raised 2026 revenue guidance to $45–47 million reflects management’s confidence in continued execution. Fundamentally, the March 2024 CMS ruling expands Medicare Part B access for MyoPro, accelerating U.S. O&P growth and supporting a large addressable market, with international revenue already up 32% year over year in Q2.

Bears say

Myomo is exposed to significant fundamental risk because its business depends on balance sheet and liquidity strength, yet it must continue funding commercialization, clinical validation, and regulatory maintenance for a specialized medical device. Its MyoPro platform also faces reimbursement uncertainty, as revenues rely on insurance billing and acceptance by providers and government customers, while competition and changing macroeconomic conditions can pressure adoption and margins. More broadly, investor sentiment toward biotech and medtech remains fragile, and any shift in healthcare priorities or failure to maintain regulatory approvals could materially impair growth and operating stability.

Myomo (MYO) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.

Myomo (MYO) Analyst Forecast & Price Prediction

Get the latest Myomo (MYO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Myomo (MYO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Myomo (MYO) Forecast

Analysts have given Myomo (MYO) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Myomo (MYO) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Myomo (MYO)


Myomo (MYO) Analyst Forecast & Price Prediction

Get the latest Myomo (MYO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Myomo (MYO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MYO stock data and trends